XENE
Xenon Pharmaceuticals Inc.
$51.21
-1.01%
$5.1B
No data for this timeframe.
Vol
Market Cap$5.1B
Cap SizeMid Cap
Analyst ConsensusStrong Buy (96%)
Inst. Holders7 funds
Inst. Value$487.6M
Inst. Activity2 buys / 1 sells
Insider Activity0B / 8S
Insider Net $-$1.7M
SEC Reports8
Press Releases2
Recent Activity
Jun 9, 2026
short_volume
Short Volume: XENE — 56.2% short (0.4M / 0.7M)
Short: 412,641 | Exempt: 0 | TRF Vol: 734,888 | Short Ratio: 56.2% | Off-exchange volume (dark pool
Jun 5, 2026
SEC
Director Gary Patou filed a Form 144 notice of intent to sell 1,322 shares of Xenon Pharmaceuticals common stock, valued
144 — Impact 2/10
Jun 5, 2026
Insider
Cannon Gillian sold 1,190 shares
Director @ $53.14 ($63.2K)
Jun 5, 2026
Insider
PATOU GARY sold 1,322 shares
Director @ $53.14 ($70.3K)
Jun 3, 2026
SEC
Xenon Pharmaceuticals filed an 8-K reporting the results of its June 2, 2026 annual meeting, where shareholders approved
8-K — Impact 3/10
Jun 3, 2026
Insider
Gover Justin D. sold 10,507 shares
Director @ $0.00 ($0.00)
May 7, 2026
SEC
Xenon Pharmaceuticals reported Q1 2026 net loss of $102.3M ($1.17/share) vs $65.0M ($0.83/share) in Q1 2025, with zero r
PRESS-RELEASE — Impact 6/10
Inst.
TWO SIGMA INVESTMENTS, LP — NEW
436,743 shares ($19.6M)
Price Targets
$79.30
+50.2% upside
Strong Buy
Current $52.79
Low $56.00
Median $80.00
High $100.00
19 analysts
$56.00
$100.00
Analyst Ratings
11Strong Buy
14Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 27, 2026 | JP Morgan | MAINTAIN | Overweight → Overweight |
| May 12, 2026 | JP Morgan | MAINTAIN | Overweight → Overweight |
| May 8, 2026 | RBC Capital | MAINTAIN | Outperform → Outperform |
| May 8, 2026 | Needham | MAINTAIN | Buy → Buy |
| Mar 16, 2026 | Wedbush | MAINTAIN | Outperform → Outperform |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-1.16 ▲ +1.3% | $-1.46 — $-0.92 | -9% YoY | 14 |
| Next Q | $-1.19 ▲ +0.9% | $-1.63 — $-0.95 | -4% YoY | 14 |
| Current FY | $-4.81 | $-5.94 — $-3.88 | -10% YoY | 16 |
| Next FY | $-5.01 ▼ -5.9% | $-6.08 — $-2.25 | -4% YoY | 16 |
Latest Reports
NEUTRAL
144
2/10
Director Gary Patou filed a Form 144 notice of intent to sell 1,322 shares of Xenon Pharmaceuticals common stock, valued
Jun 5, 2026
NEUTRAL
8-K
3/10
Xenon Pharmaceuticals filed an 8-K reporting the results of its June 2, 2026 annual meeting, where shareholders approved
Jun 3, 2026
BULLISH
Press
8/10
Xenon Pharmaceuticals presented positive Phase 3 X-TOLE2 and long-term open-label data for azetukalner in focal onset se
Apr 19, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| FMR LLC | $399.8M | — |
| VANGUARD GROUP INC | $29.8M | DOUBLED |
| TWO SIGMA INVESTMENTS, LP | $19.6M | NEW |
| MORGAN STANLEY | $13.2M | DOUBLED |
| BANK OF AMERICA CORP | $9.9M | TRIM |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 5, 2026 | Cannon Gillian | SELL | $63.2K |
| Jun 5, 2026 | PATOU GARY | SELL | $70.3K |
| Jun 3, 2026 | Gover Justin | A | $0.00 |
| Jun 3, 2026 | Machado Patrick | A | $0.00 |
| Jun 3, 2026 | Svoronos Dawn | A | $0.00 |
7 institutional holders with $487.6M total value (10,878,690 shares) as of 2025-Q4. Top holders: FMR, VANGUARD, TWO. Net buying activity: 2 institutions added/increased vs 1 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | FMR LLC | 8,920,250 | $399.8M | 82.0% | — |
| 2 | VANGUARD GROUP INC | 664,641 | $29.8M | 6.1% | DOUBLED +159.5% |
| 3 | TWO SIGMA INVESTMENTS, LP | 436,743 | $19.6M | 4.0% | NEW |
| 4 | MORGAN STANLEY | 294,332 | $13.2M | 2.7% | DOUBLED +199.3% |
| 5 | BANK OF AMERICA CORP /DE/ | 221,368 | $9.9M | 2.0% | TRIM -44.5% |
| 6 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 189,059 | $8.5M | 1.7% | NEW |
| 7 | WELLS FARGO & COMPANY/MN | 152,297 | $6.8M | 1.4% | ADD +32.2% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| TWO SIGMA INVESTMENTS, LP | NEW | — | 436,743 | — | $19.6M | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 115,221 | 152,297 | +32.2% | $6.8M | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | EXIT | 5,200 | 0 | -100.0% | $0.00 | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | TRIM | 358,432 | 199,106 | -44.5% | $8.0M | 2025-Q3 |
| UBS Group AG | TRIM | 153,058 | 106,744 | -30.3% | $4.3M | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 8,600 | 5,200 | -39.5% | $208.8K | 2025-Q3 |
| VANGUARD GROUP INC | DOUBLED | 336,514 | 873,228 | +159.5% | $27.3M | 2025-Q2 |
| MORGAN STANLEY | DOUBLED | 129,491 | 387,596 | +199.3% | $12.1M | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 136,569 | 358,432 | +162.5% | $11.2M | 2025-Q2 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 192,242 | — | $6.0M | 2025-Q2 |
| UBS Group AG | ADD | 105,333 | 153,058 | +45.3% | $4.8M | 2025-Q2 |
| WELLS FARGO & COMPANY/MN | ADD | 65,912 | 112,562 | +70.8% | $3.5M | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | NEAR_EXIT | 154,700 | 8,600 | -94.4% | $269.2K | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | EXIT | 236,983 | 0 | -100.0% | $0.00 | 2025-Q2 |
| CITADEL ADVISORS LLC | DOUBLED | 344,103 | 701,288 | +103.8% | $23.5M | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 13,700 | 154,700 | +1029.2% | $5.2M | 2025-Q1 |
| MORGAN STANLEY | ADD | 68,062 | 129,491 | +90.3% | $4.3M | 2025-Q1 |
| UBS Group AG | DOUBLED | 6,705 | 105,333 | +1471.0% | $3.5M | 2025-Q1 |
| CITADEL ADVISORS LLC | TRIM | 742,904 | 344,103 | -53.7% | $13.5M | 2024-Q4 |
| MORGAN STANLEY | TRIM | 239,942 | 68,062 | -71.6% | $2.7M | 2024-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 44,000 | 13,700 | -68.9% | $537.0K | 2024-Q4 |
| UBS Group AG | TRIM | 13,290 | 6,705 | -49.5% | $262.8K | 2024-Q4 |
10 unique insiders with 8 transactions. Net insider value: -$1.7M ($0.00 bought, $1.7M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 5, 2026 | Cannon Gillian | Director | SELL | 1,190 | $53.14 | $63.2K |
| Jun 5, 2026 | PATOU GARY | Director | SELL | 1,322 | $53.14 | $70.3K |
| Jun 3, 2026 | Gover Justin D. | Director | A | 10,507 | $0.00 | $0.00 |
| Jun 3, 2026 | Machado Patrick | Director | A | 10,507 | $0.00 | $0.00 |
| Jun 3, 2026 | Svoronos Dawn | Director | A | 1,593 | $0.00 | $0.00 |
| Jun 3, 2026 | PATOU GARY | Director | A | 10,507 | $0.00 | $0.00 |
| Jun 3, 2026 | Cannon Gillian | Director | A | 10,507 | $0.00 | $0.00 |
| Jun 3, 2026 | Cannon Gillian | Director | A | 1,593 | $0.00 | $0.00 |
| Jun 3, 2026 | Svoronos Dawn | Director | A | 10,507 | $0.00 | $0.00 |
| Jun 3, 2026 | GANNON STEVEN | Director | A | 10,507 | $0.00 | $0.00 |
| Jun 3, 2026 | GANNON STEVEN | Director | A | 1,593 | $0.00 | $0.00 |
| Jun 3, 2026 | GAROFALO ELIZABETH A. | Director | A | 10,507 | $0.00 | $0.00 |
| Jun 3, 2026 | GAROFALO ELIZABETH A. | Director | A | 1,593 | $0.00 | $0.00 |
| Jun 3, 2026 | Gover Justin D. | Director | A | 1,593 | $0.00 | $0.00 |
| Jun 3, 2026 | PATOU GARY | Director | A | 1,593 | $0.00 | $0.00 |
| Jun 3, 2026 | Machado Patrick | Director | A | 1,593 | $0.00 | $0.00 |
| Jun 1, 2026 | Machado Patrick | Director | M | 2,645 | $0.00 | $0.00 |
| Jun 1, 2026 | Cannon Gillian | Director | M | 2,645 | $0.00 | $0.00 |
| Jun 1, 2026 | Cannon Gillian | Director | M | 2,645 | $0.00 | $0.00 |
| Jun 1, 2026 | Svoronos Dawn | Director | F | 1,416 | $53.41 | $75.6K |
| Jun 1, 2026 | GANNON STEVEN | Director | M | 2,645 | $0.00 | $0.00 |
| Jun 1, 2026 | Svoronos Dawn | Director | M | 2,645 | $0.00 | $0.00 |
| Jun 1, 2026 | Svoronos Dawn | Director | M | 2,645 | $0.00 | $0.00 |
| Jun 1, 2026 | GANNON STEVEN | Director | F | 1,416 | $53.41 | $75.6K |
| Jun 1, 2026 | GANNON STEVEN | Director | M | 2,645 | $0.00 | $0.00 |
| Jun 1, 2026 | GAROFALO ELIZABETH A. | Director | M | 2,645 | $0.00 | $0.00 |
| Jun 1, 2026 | GAROFALO ELIZABETH A. | Director | M | 2,645 | $0.00 | $0.00 |
| Jun 1, 2026 | PATOU GARY | Director | M | 2,645 | $0.00 | $0.00 |
| Jun 1, 2026 | Gover Justin D. | Director | M | 2,645 | $0.00 | $0.00 |
| Jun 1, 2026 | Machado Patrick | Director | M | 2,645 | $0.00 | $0.00 |
| Jun 1, 2026 | Gover Justin D. | Director | M | 2,645 | $0.00 | $0.00 |
| Jun 1, 2026 | PATOU GARY | Director | M | 2,645 | $0.00 | $0.00 |
| May 12, 2026 | GANNON STEVEN | Director | M | 3,500 | $0.00 | $0.00 |
| May 12, 2026 | GANNON STEVEN | Director | M | 3,500 | $7.38 | $25.8K |
| Mar 13, 2026 | MORTIMER IAN | PRESIDENT & CEO | SELL | 7,308 | $55.23 | $403.6K |
| Mar 13, 2026 | KENNEY CHRISTOPHER JOHN | Chief Medical Officer | SELL | 1,410 | $55.23 | $77.9K |
| Mar 13, 2026 | DiFabio Andrea | Chief Legal Officer | SELL | 1,342 | $55.23 | $74.1K |
| Mar 12, 2026 | KENNEY CHRISTOPHER JOHN | Chief Medical Officer | M | 3,750 | $0.00 | $0.00 |
| Mar 12, 2026 | DiFabio Andrea | Chief Legal Officer | M | 3,750 | $0.00 | $0.00 |
| Mar 12, 2026 | MORTIMER IAN | PRESIDENT & CEO | M | 12,500 | $0.00 | $0.00 |
| Mar 12, 2026 | KENNEY CHRISTOPHER JOHN | Chief Medical Officer | M | 3,750 | $0.00 | $0.00 |
| Mar 12, 2026 | MORTIMER IAN | PRESIDENT & CEO | M | 12,500 | $0.00 | $0.00 |
| Mar 12, 2026 | DiFabio Andrea | Chief Legal Officer | M | 3,750 | $0.00 | $0.00 |
| Mar 10, 2026 | KENNEY CHRISTOPHER JOHN | Chief Medical Officer | SELL | 2,771 | $60.11 | $166.6K |
| Mar 10, 2026 | MORTIMER IAN | PRESIDENT & CEO | SELL | 11,269 | $60.11 | $677.4K |
| Mar 10, 2026 | DiFabio Andrea | Chief Legal Officer | SELL | 2,607 | $60.11 | $156.7K |
| Mar 9, 2026 | DiFabio Andrea | Chief Legal Officer | M | 7,500 | $0.00 | $0.00 |
| Mar 9, 2026 | DiFabio Andrea | Chief Legal Officer | A | 7,500 | $0.00 | $0.00 |
| Mar 9, 2026 | KENNEY CHRISTOPHER JOHN | Chief Medical Officer | M | 7,500 | $0.00 | $0.00 |
| Mar 9, 2026 | KENNEY CHRISTOPHER JOHN | Chief Medical Officer | A | 7,500 | $0.00 | $0.00 |
8 SEC filing reports analyzed. Sentiment: 0 bullish, 3 bearish, 1 mixed, 4 neutral. Avg impact: 4.0/10.
NEUTRAL
144
2/10
Director Gary Patou filed a Form 144 notice of intent to sell 1,322 shares of Xenon Pharmaceuticals
Jun 5, 2026
NEUTRAL
8-K
3/10
Xenon Pharmaceuticals filed an 8-K reporting the results of its June 2, 2026 annual meeting, where s
Jun 3, 2026
MIXED
PRESS-RELEASE
6/10
Xenon Pharmaceuticals reported Q1 2026 net loss of $102.3M ($1.17/share) vs $65.0M ($0.83/share) in
May 7, 2026
NEUTRAL
DEFA14A
2/10
Xenon Pharmaceuticals filed a definitive proxy statement for its 2025 annual meeting, proposing the
Apr 22, 2026
BEARISH
PRESS-RELEASE
5/10
Xenon Pharmaceuticals reported a Q4 2025 EPS miss of -9.4% versus consensus, with actual EPS at $-1.
Apr 15, 2026
NEUTRAL
8-K
3/10
Xenon Pharmaceuticals amended and restated its 2025 Inducement Equity Incentive Plan to increase the
Apr 13, 2026
BEARISH
PRESS-RELEASE
5/10
Xenon Pharmaceuticals (XENE) reported a Q4 2025 earnings miss with EPS of -$1.31 versus consensus of
Apr 7, 2026
BEARISH
CLUSTER
6/10
Three executive insiders at Xenon Pharmaceuticals (XENE) sold shares worth over $550K in open-market
Mar 14, 2026
Current analyst consensus: Strong Buy (96% buy). Based on 26 analysts: 11 strong buy, 14 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$79.30 mean target
+50.2% upside
Strong Buy (1.15)
$56.00 Low
$100.00 High
| Metric | Value |
|---|---|
| Current Price | $52.79 |
| Target Low | $56.00 |
| Target Mean | $79.30 |
| Target Median | $80.00 |
| Target High | $100.00 |
| # Analysts | 19 |
| Recommendation | Strong Buy (1.15) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-1.16 | $-1.46 | $-0.92 | -8.5% | +1.3% | 7↑ 4↓ | $0.0B | 0.0% | 14 |
| Next Q 2026-09-30 |
$-1.19 | $-1.63 | $-0.95 | -3.9% | +0.9% | 8↑ 3↓ | $0.0B | 0.0% | 14 |
| Current FY 2026-12-31 |
$-4.81 | $-5.94 | $-3.88 | -10.3% | +0.3% | 6↑ 7↓ | $0.0B | -72.5% | 16 |
| Next FY 2027-12-31 |
$-5.01 | $-6.08 | $-2.25 | -4.1% | -5.9% | 4↑ 9↓ | $0.0B | 1602.7% | 16 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-1.161 | |
| 7d ago | $-1.161 | |
| 30d ago | $-1.177 | +0.016 |
| 60d ago | $-1.183 | +0.022 |
| 90d ago | $-1.193 | +0.032 |
9 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 27, 2026 | JP Morgan | MAINTAIN | Overweight | Overweight |
| May 12, 2026 | JP Morgan | MAINTAIN | Overweight | Overweight |
| May 8, 2026 | RBC Capital | MAINTAIN | Outperform | Outperform |
| May 8, 2026 | Needham | MAINTAIN | Buy | Buy |
| Mar 16, 2026 | Wedbush | MAINTAIN | Outperform | Outperform |
| Mar 10, 2026 | Wells Fargo | MAINTAIN | Overweight | Overweight |
| Mar 10, 2026 | Wedbush | MAINTAIN | Outperform | Outperform |
| Mar 10, 2026 | Deutsche Bank | MAINTAIN | Buy | Buy |
| Mar 10, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Mar 9, 2026 | Needham | MAINTAIN | Buy | Buy |
| Mar 9, 2026 | Baird | MAINTAIN | Outperform | Outperform |
| Feb 27, 2026 | Needham | MAINTAIN | Buy | Buy |
| Feb 27, 2026 | Wells Fargo | MAINTAIN | Overweight | Overweight |
| Feb 24, 2026 | Wolfe Research | INITIATE | — | Outperform |
| Jan 9, 2026 | JP Morgan | MAINTAIN | Overweight | Overweight |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 11 | 14 | 1 | 0 | 0 | 96% | |
| May 1, 2026 | 11 | 14 | 1 | 0 | 0 | 96% | |
| Apr 1, 2026 | 11 | 14 | 1 | 0 | 0 | 96% | |
| Mar 1, 2026 | 11 | 15 | 1 | 0 | 0 | 96% | |
| Feb 1, 2026 | 10 | 15 | 1 | 0 | 0 | 96% | |
| Jan 1, 2026 | 10 | 15 | 1 | 0 | 0 | 96% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 9, 2026
short_volume
Short Volume: XENE — 56.2% short (0.4M / 0.7M)
Short: 412,641 | Exempt: 0 | TRF Vol: 734,888 | Short Ratio: 56.2% | Off-exchange volume (dark pool + OTC)
May 29, 2026
other
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
<p align="justify">VANCOUVER, British Columbia and BOSTON, MA, May 29, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuros
May 14, 2026
Clinical Trial
A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures
Phase Phase 3 — COMPLETED
May 12, 2026
earnings_calendar
XENE Q1 2026 Earnings After Market Close — 2026-05-12
May 7, 2026
earnings
Xenon Reports Q1 2026 Financial Results and Provides Business Update
<p>VANCOUVER, British Columbia and BOSTON, MA, May 07, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused b
May 7, 2026
earnings_calendar
XENE Q1 2026 Earnings After Market Close — 2026-05-07
Apr 19, 2026
fda
Xenon Presents Azetukalner Phase 3 X-TOLE2 Study Results and 48-Month Long-term Data in Focal Onset Seizures at 2026 AAN Annual Meeting
<p>VANCOUVER, British Columbia and BOSTON, MA, April 19, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused
Apr 15, 2026
earnings
Xenon to Present at Upcoming Investor Conferences
<p align="left">VANCOUVER, British Columbia and BOSTON, MA, April 15, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neurosci
Apr 7, 2026
earnings
Xenon to Highlight Phase 3 X-TOLE2 & Long-Term Data for Azetukalner in Focal Onset Seizures at 2026 AAN Annual Meeting
<p align="left">VANCOUVER, British Columbia and BOSTON, MA, April 07, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neurosci
Apr 1, 2026
clinical_trial_readout
Results Pending: XEN1101 (Phase 3) — Completed 79d ago
Trial: A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures
Sponsor: Xenon Pharmaceuticals Inc.
Phase: Phase 3 | Completed: 2026-01-12
Mar 30, 2026
clinical_trial_readout
Results Pending: XEN1101 (Phase 3) — Completed 77d ago
Trial: A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures
Sponsor: Xenon Pharmaceuticals Inc.
Phase: Phase 3 | Completed: 2026-01-12
Mar 12, 2026
offering
Xenon Pharmaceuticals Announces Closing of $747.5 Million Upsized Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
<p align="left">VANCOUVER, British Columbia and BOSTON, MA, March 12, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neurosci
Mar 11, 2026
offering
Xenon Pharmaceuticals Announces Pricing of Upsized $650.0 Million Public Offering
<p align="justify">VANCOUVER, British Columbia and BOSTON, March 10, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscie
Mar 10, 2026
short_interest
FTD: XENE — 48,878 shares ($3.1M) failed to deliver
Settlement: 20260310, Price: $62.76, FTD Value: $3,067,583.28, XENON PHARMACEUTICALS INC COMM
Mar 9, 2026
offering
Xenon Pharmaceuticals Announces Proposed Public Offering
<p>VANCOUVER, British Columbia and BOSTON, MA, March 09, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused
Mar 9, 2026
fda
Xenon Announces Positive Topline Data from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures (FOS)
<p>VANCOUVER, British Columbia and BOSTON, MA, March 09, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused